News & Updates

In patients who are hospitalized for COVID-19, treatment with empagliflozin does not appear to have any positive impact on outcomes such as 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death, as shown in the open-label RECOVERY trial.

The novel, selective, dual PDE*3 and PDE4 inhibitor ensifentrine improved lung function and reduced exacerbations in individuals with chronic obstructive pulmonary disease (COPD), findings from the ENHANCE**-1 and ENHANCE-2 trials have shown.

Gut-brain interaction disorders and persistent gastrointestinal (GI) symptoms prevail 12–18 months following COVID-19 hospitalization, and these prolonged GI issues are associated with the severity of the symptoms during hospitalization and the psychological toll of the illness experience, according to a study.

Asthma is a highly prevalent disease that can affect anybody regardless of age, race, and location. The overall burden of asthma remains severe. Despite the range of available therapies and well-established guidelines, there remains a significant unmet need in the management of asthma. [BMC Public Health 2012;12:860; Respir Res 2023;24:169; Eur Respir J 2014;43:343-373]

In the CONFIDENT trial, convalescent plasma (CCP) conferred a mortality benefit for patients with COVID-19-induced acute respiratory distress syndrome (ARDS) who were on invasive mechanical ventilation (IMV).

In the phase III BOREAS trial, the monoclonal antibody dupilumab conferred multiple benefits for individuals with chronic obstructive pulmonary disease (COPD) and type 2 (T2) inflammation.